

Resource Summary Report

Generated by NIF on Aug 30, 2026

Netherlands Brain Bank

RRID:SCR_013841

Type: Tool

Proper Citation

Netherlands Brain Bank (RRID:SCR_013841)

Resource Information

URL: <http://www.brainbank.nl>

Proper Citation: Netherlands Brain Bank (RRID:SCR_013841)

Description: A biomaterial supply resource which collects, stores, and disseminates diseased and healthy brain tissue. The Netherlands Brain Bank currently contains more than 3600 samples, and each sample includes a neuropathological report and donor medical history. The samples can additionally be matched with ante-mortem parameters and post-mortem parameters upon request. Sample types include cortex, spinal cord, cerebrospinal fluid, plasma, and DNA, among others. Database mining is available with a financial contribution.

Abbreviations: NBB

Resource Type: biomaterial supply resource, material resource

Keywords: biomaterial supply resource, brain, brain tissue, brain bank, diseased tissue, healthy tissue, FASEB list

Funding: Stichting MS Research ;
Vrienden Loterij ;
Stichting Parkinson Fonds ;
Hersenstichting Nederland Breinbekend Werk ;
Zabawas ;
private donations

Availability: Free, Available to the research community, The community can contribute to this resource, Some services require a contribution

Resource Name: Netherlands Brain Bank

Resource ID: SCR_013841

Record Creation Time: 20220129T080318+0000

Record Last Update: 20260829T183106+0000

Ratings and Alerts

No rating or validation information has been found for Netherlands Brain Bank.

No alerts have been found for Netherlands Brain Bank.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 186 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Mueller A, et al. (2026) In-vitro interaction studies between the amyloid PET tracer florbetaben and the amyloid-beta targeting antibodies lecanemab and donanemab on AD brain samples reveal no interferences. *Alzheimer's research & therapy*, 18(1).

Arafa D, et al. (2026) Myelin sheaths in the central nervous system can withstand damage and dynamically remodel. *Science (New York, N.Y.)*, 391(6786), eadr4661.

Ruf WP, et al. (2026) Multi-modal dissection of cell-type specific TDP-43 pathology in the motor cortex. *Nature communications*, 17(1).

Engelenburg HJ, et al. (2026) Protocol for isolating viable human central nervous system T cells. *STAR protocols*, 7(2), 104464.

Dunot J, et al. (2026) AETA peptide contributes to Alzheimer's disease signature of synapse dysfunction. *Acta neuropathologica*, 151(1).

Leboeuf M, et al. (2026) Reevaluating the role of beta2-microglobulin: new insights on selective vulnerability in ALS pathology. *Acta neuropathologica*, 151(1).

Zachrisson O, et al. (2026) Exidavnemab binds to aggregated γ -synuclein in human brains affected by γ -synucleinopathies. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*, 23(1), e00779.

Bolsewig K, et al. (2026) A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders. *Nature medicine*, 32(3), 1073.

Honey MIJ, et al. (2026) An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration. *Nature medicine*, 32(6), 2083.

Preitner N, et al. (2026) Elimination of tau tangles and soluble aggregates with the small molecule ACI-16664 prevents neurodegeneration in vivo. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 22(7), e71572.

Stellingwerf A, et al. (2026) Evaluating Basigin as a Potential Biomarker of Blood-Brain Barrier Dysfunction in Cerebral Amyloid Angiopathy. *Neuropathology and applied neurobiology*, 52(1), e70064.

Klavert J, et al. (2026) Charting the human-specific properties of gene expression networks in the infant prefrontal cortex. *Science advances*, 12(23), eaea3316.

Müller-Schiffmann A, et al. (2025) Oxidized MIF is an Alzheimer's disease drug target relaying external risk factors to tau pathology. *Cell reports. Medicine*, 102520.

Ciccaldò M, et al. (2025) A novel allosteric GCase modulator prevents Tau accumulation in GBA1WT and GBA1L444P/L444P cellular models. *Scientific reports*, 15(1), 17646.

Rocha FM, et al. (2025) Mapping reactive astrogliosis in Parkinson's brain with astroglial tracers BU99008 and Deprenyl: New insights from a multi-marker postmortem study. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(2), e14488.

Theologidis V, et al. (2025) Bradykinesia and postural instability in a model of prodromal synucleinopathy with α -synuclein aggregation initiated in the gigantocellular nuclei. *Acta neuropathologica communications*, 13(1), 32.

Ivan T, et al. (2025) Aggregation-Dependent Epitope Sequence and Modification Fingerprints of Anti-A β Antibodies. *bioRxiv : the preprint server for biology*.

Vokali E, et al. (2025) Development of [18F]ACI-19626 as a first-in-class brain PET tracer for imaging TDP-43 pathology. *Nature communications*, 16(1), 9358.

Weidling I, et al. (2025) hiPSC-neurons recapitulate the subtype-specific cell intrinsic nature of susceptibility to neurodegenerative disease-relevant aggregation. *Acta neuropathologica communications*, 13(1), 108.

Orr N, et al. (2025) Epstein-Barr virus and the immune microenvironment in multiple sclerosis: Insights from high-dimensional brain tissue imaging. *Proceedings of the National Academy of Sciences of the United States of America*, 122(11), e2425670122.